 Shares of Axsome Therapeutics NASDAQ: AXSM are up more than 30 today on news that the biopharmaceutical company has received approval from the U.S. Food and Drug Administration FDA for a unique, first-of-its-kind depression treatment. Specifically, the FDA has approved Axsome Therapeutics new drug Auvelity, extended-release tablets that are used to treat major depressive disorders MDD in adults. 